Publications

Research Articles

Mellinghoff I., Daibata M., Humphreys R.E., Mulder C., Takada K., and Sairenji T. (1991). Early events in Epstein-Barr virus genome expression after activation: regulation by second messengers of B cell activation. Virology, 185, 922-928.

Daibata D., Mellinghoff I., Takagi S., Humphreys R.E., and Sairenji T. (1991). Effect of Genistein, a tyrosine kinase inhibitor, on latent EBV activation by cross-linkage of membrane IgG in Akata B cells. Journal of Immunology, 147, 292-297.

Marder V.J. and Mellinghoff I.K. Cocaine and Buerger Disease (2000). Is there a pathogenetic association? Archives of Internal Medicine, 160, 2057-2060.

Neshat MS, Mellinghoff, I.K., Tran, C., Stiles, B., Thomas, G., Petersen, R., Frost, P., Gibbons, J.J., Wu, H., and Sawyers, C.L. (2001). Enhanced sensitivity of PTEN deficient tumors to inhibition of FRAP/mTOR. Proc Natl Acad Sci U S A 98, 10314-10319.

Mellinghoff I.K., Winston D.J., Mukwaya G., and Schiller G.J. (2002) Scedosporium apiospermum brain abscesses treated with posaconazole. Clinical Infectious Diseases, 34, 1648-1650.

Mellinghoff, I.K., Tran, C., and Sawyers, C.L. (2002). Growth inhibitory effects of the dual ErbB1/ErbB2 tyrosine kinase inhibitor PKI-166 on human prostate cancer xenografts. Cancer Res 62, 5254-5259.

Gera, J.F., Mellinghoff, I.K., Shi, Y., Rettig, M.B., Tran, C., Hsu, J.H., Sawyers, C.L., and Lichtenstein, A.K. (2004). AKT activity determines sensitivity to mammalian target of rapamycin (mTOR) inhibitors by regulating cyclin D1 and c-myc expression. J Biol Chem 279, 2737-2746.

Mellinghoff, I.K., Vivanco, I., Kwon, A., Tran, C., Wongvipat, J., and Sawyers, C.L. (2004). HER2/neu kinase-dependent modulation of androgen receptor function through effects on DNA binding and stability. Cancer Cell 6, 517-527.

Waldherr, C., Mellinghoff, I.K., Tran, C., Halpern, B., Rozengurt, N., Safaei, A., Weber, W.A. , Stout, D., Satyamurthy, N., Barrio, J., Phelps, M.E., Silverman, D.H., Sawyers, C.L., and Czernin, J. (2005). Monitoring antiproliferative responses to kinase inhibitor therapy in mice with 3'-deoxy 3'-18Ffluorothymidine PET. J Nucl Med 46, 114-120.

Mellinghoff, I.K., Wang, M., Vivanco, I., Haas-Kogan, D., Zhu, S., Dia, E., Lu, K., Yoshimoto, K., Huang, J., Chute, D., Riggs, B.., Horvath, S., Liau, L., Cavenee, W., Rao, P., Beroukhim, R., Peck, T., Lee, J., Sellers, W., Stokoe, D., Prados, M., Cloughesy, T.F., Sawyers, C.L., Mischel, P.S. (2005). Molecular determinants of EGFR kinase inhibitor response in glioblastoma. The New England Journal of Medicine.
353, 2012-2024.

Thomas G.V., Tran C., Mellinghoff I.K., Welsbie D.S., Chan E., Fueger B., Czernin J., Sawyers C.L. (2006). Hypoxia-inducible factor determines sensitivity to mTOR inhibitors in kidney cancer. Nature Medicine. 1, 122-127.

Xin L, Teitell M.A, Lawson D.A., Kwon A., Mellinghoff I.K., and Witte O.N. (2006). Progression of prostate cancer by synergy of Akt with genotropic and nongenotropic actions of the androgen receptor. Proc Natl Acad Sci U S A 103, 7789-7794.

Beroukhim R., Lin M., Park Y., Hao K., Zhao X., Garraway L.A., Fox E.A., Hochberg E.P., Mellinghoff I.K., Hofer M.D., Descazeaud A., Rubin M.A., Meyerson M., Wong W.H., Sellers W.R., and Li C. (2006). Inferring loss-of-heterozygosity from unpaired tumors using high-density SNP-Arrays. PLoS Comput Biol 2(5); e41.

Wang M.Y., Lu K.V., Zhu S., Dia E.Q., Vivanco I., Shackleford G.M., Cavenee W., Mellinghoff I.K., Cloughesy T., Sawyers C.L., and Mischel P.S. (2006). Mammalian Target of Rapamycin Inhibition Promotes Response to Epidermal Growth Factor Receptor Kinase Inhibitors in PTEN-deficient and PTEN-intact glioblastoma cells. Cancer Res 66(16): 7864-7869.

Lee J.C., Vivanco I., Beroukhim R., Huang J.H.Y., Feng W.L., DeBiasi R.M., Yoshimoto K., King J.C., Nghiemphu P., Yuza Y., Xu Q., Greulich H., Thomas R., Paez G., Peck T., Linhart D.J., Glatt K.A., Getz G., Onofrio R., Ziaugra L., Levine R.L., Gabriel S., Kawaguchi T., O'Neill K., Khan H., Liau L.M., Nelson S., Rao P.N., Mischel P., Pieper R., Cloughesy T., Leahy D.J., Sellers W.R., Sawyers C.L., Meyerson M., and Mellinghoff I.K. (2006). EGFR activation in glioblastoma through novel missense mutations in the extracellular domain. PLoS Medicine. 12 (3): e485.

Thomas R.K., Baker A.C., DeBiasi R., Winckler W., LaFramboise T., Lin W., Wang M., Feng W., Zander T., MacConnaill L., Lee J.C., Nicoletti R., Hatton C., Goyette M., Girard L., Majmudar K., Ziaugra L., Wong K.K., Gabriel S., Beroukhim R., Peyton M., Barretina J., Dutt A., Emery C., Greulich H., Shah K., Sasaki H., Gazdar A.F., Minna J., Armstrong S., Mellinghoff I.K., Hodi F., Dranoff G., Mischel P., Cloughesy T., Nelson S., Liau L., Mertz K., Rubin M., Moch H., Loda M., Catalona W., Fletcher J., Signoretti S., Kaye F., Anderson K.C., Demetri G., Dummer R., Wagner S., Herlyn M., Sellers W.R., Meyerson M., Garraway L.A. (2007). High-throughput oncogene mutation profiling in human cancer. Nature Genetics. 39 (3): 1-5.

Carlson M.R., Pope W.B., Horvath S., Braunstein J.G., Nghiemphu P., Tso C.L., Mellinghoff I.K., Lai A., Liau L.M., Mischel P.S., Dong J., Nelson S.F., Cloughesy T.F. (2007). Relationship between Survival and Edema in Malignant Gliomas: role of Vascular Endothelial Growth Factor and Neuronal Pentraxin 2. Clin Cancer Res. 13 (9): 2592-2598.

Vivanco I., Palaskas N., Tran C, Finn SP, Getz G, Kennedy NJ, Jiao J, Rose J, Xie W, Loda M, Golub T, Mellinghoff I.K., Davis RJ, Wu H, Sawyers CL. (2007). Identification of the JNK Signaling Pathway as a Functional Target of the Tumor Suppressor PTEN. Cancer Cell. 11: 555-569.

Yoshimoto K., Dang J., Zhu S, Nathanson D., Huang T., Dumont R., Seligson D.B., Yong W.H., Xiong Z., Rao N., Winther H., Chakravarti A., Bigner D.D., Mellinghoff I.K., Horvath S., Cavenee W.K., Cloughesy T.F., Mischel P.S. Development of a Real-time RT-PCR Assay for Detecting EGFRvIII in Glioblastoma Samples. Clin Cancer Res. 2008 Jan 15;14(2):488-493.

Cloughesy TF, Yoshimoto K, Nghiemphu P, Brown K, Dang J, Zhu S, Hsueh T, Chen Y, Wang W, Youngkin D, Liau L, Martin N, Becker D, Bergsneider M, Lai A, Green R, Oglesby T, Koleto M, Trent J, Horvath S, Mischel PS, Mellinghoff IK, Sawyers CL. Antitumor Activity of Rapamycin in a Phase I Trial for Patients with Recurrent PTEN-Deficient Glioblastoma. PLoS Med. 2008 Jan 22;5(1):e8.

Beroukhim R, Getz G, Nghiemphu L, Barretina J, Hsueh T, Linhart D, Vivanco I, Lee JC, Huang JH, Alexander S, Du J, Kau T, Thomas RK, Shah K, Soto H, Perner S, Prensner J, Debiasi RM, Demichelis F, Hatton C, Rubin MA, Garraway LA, Nelson SF, Liau L, Mischel PS, Cloughesy TF, Meyerson M, Golub TA, Lander ES, Mellinghoff IK, Sellers WR. Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma. Proc Natl Acad Sci USA. 2007 Dec 11;104(50):20007-12. Epub 2007 Dec 6.

Invited Reviews, Editorials, and Book Chapters

Mellinghoff, I. and Sawyers, C.L. (2000) Kinase Inhibitor Therapy in Cancer. PPO Updates, Principles & Practice of Oncology, Vincent T. Devita, Jr., Samuel Hellman, Steven A. Rosenberg (Eds). 5th Edition. Lippincott Williams & Wilkins 14(12):1-11.

Mellinghoff I.K., Sawyers C.L. (2002). The emergence of resistance to targeted cancer therapeutics. Pharmacogenomics, 3(5):603-623.

Mellinghoff, I.K., and Sawyers, C.L. (2004). TORward AKTually useful mouse models. Nature Medicine 10, 579-580.

Mellinghoff, I.K. (2006) Novel Approaches to Androgen Receptor Blockade. In: Prostate Cancer: Translational and Emerging Therapies. N. A. Dawson and W. K. Kelly (editors), Taylor and Francis Publishing Group.

Mellinghoff, I.K, Cloughesy T.F., Mischel, P.M. (2007). Molecular Pathways: PTEN-mediated resistance to EGFR kinase inhibitors. Clinical Cancer Research, 15: 378-81.

Mellinghoff I.K. (2007) Why Do Cancer Cells Become "Addicted" to Oncogenic Epidermal Growth Factor Receptor? PLoS Medicine, 4 (10), e321.

Site Map \| Index	Legal Disclaimer \| Privacy Practices \| Public Notices

©2009 Memorial Sloan-Kettering Cancer Center. 212-639-2000 1275 York Avenue New York, NY 10065.	PublicAffairs@mskcc.org